Patients who have completed treatment for endometrial cancer recurrence often ask how likely the disease is to return and what signs to watch for.
Recurrence Risk Overview
A 2024 study in Frontiers in Oncology reports that roughly 15% to 20% of patients experience a return of the disease.
Individual risk depends on tumor stage, grade, molecular subtype and the specific therapies received, said Josephine Kim, MD, a gynecologic oncologist at City of Hope Orange County.
Low-grade tumors confined to the uterus usually carry a lower chance of return than high-grade or spread disease, Dr. Kim noted.
Most recurrences appear within the first two to three years after therapy, prompting more frequent follow-up visits during that window.
Four molecular subtypes add further nuance to risk assessment, explained James Hamrick, MD, MPH, chairman of the Caris Life Sciences Precision Oncology Alliance.
POLE-mutated cancers have an excellent prognosis and a very low likelihood of return, especially when detected early.
Mismatch-repair-deficient tumors show an intermediate risk and tend to respond well to immunotherapy agents.
p53-abnormal cancers behave more aggressively and are associated with a higher probability of recurrence, influencing post-surgical treatment plans.
NSMP, or “no specific molecular profile,” includes a mixed group; lower-grade, estrogen-receptor-positive cases fare better than higher-grade, receptor-negative tumors.
Understanding a patient’s molecular subtype helps clinicians tailor surveillance intensity, though it cannot predict outcomes for any single individual.
Follow-up Care Guidelines
The American Cancer Society advises a physical exam every three to six months for the first two to three years, then every six to twelve months through year five.
If exams are normal and no symptoms are present, routine blood work or imaging is not required; scans are ordered only when clinical findings suggest a problem.
Patients should report new vaginal bleeding, persistent pelvic pain, unexplained weight loss, or a lingering cough promptly, as these may signal recurrence.
Recurrence often first appears at the vaginal cuff—the closed top of the vagina after hysterectomy—though it can also arise in pelvic lymph nodes, the abdomen, or the lungs.
A recurrence limited to the vagina can sometimes be treated with the goal of curing it, particularly if you have not previously received radiation there.
For distant or multiple sites, treatment typically shifts to systemic therapies such as chemotherapy combined with immunotherapy, hormone therapy for hormone-receptor-positive tumors, or targeted agents based on biomarker results.
Recent FDA approvals include Jemperli (dostarlimab) plus chemotherapy for MMR-deficient or MSI-high disease, Keytruda (pembrolizumab) plus chemotherapy for advanced disease, and Imfinzi (durvalumab) plus chemotherapy for MMR-deficient cases that have progressed after other treatments.
Managing Uncertainty After Treatment
Discussing the likelihood of cancer returning often begins with a conversation about the tumor’s biological profile. Patients are encouraged to ask their physicians which molecular classification applies to their disease and how that information shapes surveillance recommendations. Even when the subtype suggests a lower probability of recurrence, clinicians stress that it does not guarantee an outcome for any individual.
